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We investigated the risk factors for venous thrombosis in cancer patients with implantable ports undergoing chemotherapy. One
hundred and seventy one ports were placed in a central (‘‘chest ports’’) and 84 in a peripheral vein (‘‘arm ports’’), 181 received pro-
phylactic nadroparin and 10 coumarin. Clinically overt thrombosis was conﬁrmed by ultrasound or angiography. Catheter-related
thrombosis incidence without anticoagulants was 28% in arm and 33% in chest ports, but with anticoagulants this was 32% in arm
and only 1% in chest ports (odds ratio (OR) 34.8 95% conﬁdence interval (CI) 7.3–165). Left-sided placement compared with right-
sided and catheter tip position in the superior vena cava compared with right atrium were associated with a 3.5 respectively 2.6-fold
increased risk. Thrombosis was associated with elevated homocysteine levels (OR = 3.8, 95% CI 1.3–11.3), but not with factor V
Leiden or prothrombin 20210A gene mutations, or high concentration of factor VIII, IX or XI. Prophylaxis with anticoagulants
is recommended for chest, but not for arm ports. Determination of plasma homocysteine levels may identify patients at an increased
risk for thrombosis.
 2004 Elsevier Ltd. All rights reserved.
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The use of centrally or peripherally inserted venous
catheters with implantable ports has become common
in cancer patients receiving chemotherapy. Catheters
are implanted for the long-term administration of
chemotherapy courses with sclerosing agents, in patients
with toxic chemotherapy regimens and anticipated
haematological toxicity requiring frequent blood sam-
pling and, more recently, in patients who require contin-
uous administration of drug infusions. Many diﬀerent
types of implantable devices consisting of a small-vol-
ume subcutaneous injection (s.c.) port (commonly called
ports) have been introduced with diﬀerent types of cath-0959-8049/$ - see front matter  2004 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejca.2004.06.023
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5266760.
E-mail address: s.osanto@lumc.nl (S. Osanto).eters and devices. Port-associated complications such as
infections, thrombosis or even pulmonary embolism, are
the cause of signiﬁcant morbidity and occasionally mor-
tality and remain a signiﬁcant problem in current daily
practice.
Catheter-related thrombosis is probably frequently
under-diagnosed as most patients with catheter-related
thrombosis are asymptomatic or have non-speciﬁc
symptoms. The reported incidence of catheter-related
venous thrombosis varies considerably, in part due to
the method of detecting thrombi, with incidences of
greater than 60% being reported [1,2]. De Cicco and col-
leagues [1] reported a very high incidence of 66%, but
only 6% of patients with catheter-related thrombosis,
screened by venography, were symptomatic. Lokich
and colleagues [3] reported an incidence of 42%, of
which 28.3% were symptomatic. Van Roode and col-
leagues [4] showed that in patients with haematological
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clinical thrombosis, of whom nine became clinically
manifest. Clinical presentation of catheter-related
thrombosis may include arm or head swelling, erythema,
pain and congestion of collateral veins, whereas catheter
malfunctioning may be the ﬁrst clinical manifestation of
an otherwise asymptomatic catheter-related thrombosis.
Thrombosis may lead to prompt catheter removal and
anticoagulant treatment.
A hypercoagulable state associated with malignancy,
co-morbidity of cancer patients, the use of certain anti-
cancer drugs and the presence of a foreign body may
contribute to the higher venous thrombosis incidence
observed in cancer patients [5]. Thrombogenicity of dif-
ferent central venous catheters has been reported to vary
depending on the catheter material and size of the cath-
eter used. Polyethylene catheters are associated with a
higher incidence than silastic catheters [6,7], whereas
there is no diﬀerence in the incidence of venous throm-
bosis following the use of silastic or hydromer-coated
polyurethane catheters [6,7].
While several factors may contribute to the develop-
ment of venous thrombosis, few of these factors have
been examined in well-controlled studies [8,9]. We there-
fore investigated various risk factors and the incidence
of catheter-related thrombosis in a cohort of cancer pa-
tients undergoing chemotherapy and determined the risk
of catheter-related thrombosis associated with anticoag-
ulant treatment and prothrombotic risk factors.Table 1
Patients characteristics
Patients with thrombosis
n (%)
Gender
Female 19 (57.6)
Male 14 (42.4)
Median age in years (range) 42 (16–67)
Type of tumour
osteo-or Ewings sarcoma 19 (57.6)
oesophagus/stomach 7 (21.2)
ovarian 5 (15.2)
mamma 0 (0.0)
miscellaneous 2 (6.1)
Metastatic disease 15 (45.5)
Chemotherapeutic agents
anthracyclines 26 (78.8)
cisplatin 28 (84.8)
taxane 5 (15.2)
5-FU civ 8 (24.2)
Platelet count (*10
9 cells/L)
6400 4 (12.1)
>400 29 (87.9)
OR, odds ratio; 95% CI, 95% conﬁdence interval; 5-Fu, 5-ﬂuorouracil; civ,2. Patients and methods
2.1. Patients
Between April 1994 and January 2003, 243 consecu-
tive cancer patients in the Leiden University Medical
Centre Department of Clinical Oncology received a cen-
tral venous catheter for either repeated administration
of chemotherapy with sclerosing agents known to irri-
tate the veins resulting in frequent phlebitis or for con-
tinuously infused chemotherapy. Patients were treated
with various combination chemotherapy regimens, most
of which contained cisplatin, doxorubicin or both
cisplatin and (epi)-doxorubicin. Of these patients, 132
were men and 111 were women, with a mean age of
44 years (range 14–78 years). The most frequently trea-
ted types of cancer were bone tumours, i.e., osteosar-
coma or Ewings sarcoma (124 [51%] patients) and
distal oesophagus or stomach cancer (54 [22%] patients)
(Table 1). One hundred and thirty-nine (57%) patients
had distant metastases at the time of insertion of the
catheter.
2.2. Implantable ports
All catheters implanted were composed of two
parts, namely a single lumen radio-opaque catheter
connected to an injection reservoir, the port, contain-
ing a silicone diaphragm. For the chest ports, we usedPatients without thrombosis OR (95% CI)
n (%)
92 (43.8) 1
118 (56.2) 0.6 (0.3–1.2)
44 (14–78)
105 (50.0) 1.4 (0.7–2.9)
47 (22.4) 2.1 (0.9–5.3)
9 (4.3) 5.6 (1.5–20.4)
12 (5.7)
37 (17.6) 0.9 (0.4–1.7)
124 (59.0) 1.8 (0.7–4.2)
171 (81.4) 0.7 (0.2–3.0)
156 (74.3) 0.5 (0.2–1.4)
13 (6.2) 0.3 (0.1–1.8)
72 (34.3) 1.6 (0.4–3.5)
28 (13.3) 1
182 (86.7) 1.1 (0.4–3.5)
continuous infusion.
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the arm ports, either a Port-a-Cath (Smiths Medical
Deltec) or a Vital port (Cook Pacemaker Corporation,
Leechburg, PA). The injection port reservoir of the
chest ports was made of Titanium and the catheter
of polyurethane, with an outer diameter of 2.6 mm
and an inner diameter of 1.6 mm. Arm ports also
had a Titanium reservoir and the material of the
catheter was made of polyurethane in the Deltec and
of silastic in the Vital Cook catheters. The outer dia-
meter of the Deltec catheter was 1.9 mm; the internal
diameter was 1.0 mm. The outer diameter of the Vital
Cook catheter was 1.7 mm; the inner diameter was 0.9
mm. All catheters were introduced into the veins by
experienced interventional radiologists in the angiogra-
phy interventional radiology suite. Under local anaes-
thesia, the catheter was tunnelled and a surgeon made
the connection between the reservoir and catheter dur-
ing the same session. After placement, correct posi-
tioning of the tip of the catheter was conﬁrmed by
chest X-ray and shown to be localised in either the
vena cava superior or the right atrium. In general,
ports were not immediately removed after cessation
of chemotherapy in order to be able to use the ports
for second- or third-line chemotherapy, if needed.
Experienced nurses ﬂushed all ports every 4–6 weeks
with 5 ml of a heparin-sodium solution 100 IE/ml
and at the end of each cycle of chemotherapy infu-
sions to maintain patency. In patients in whom the
port was replaced, the time period of insertion of both
catheters was analysed. Chest ports were placed in the
subclavian vein, but preferably in the jugular vein.
Arm ports were placed in an arm vein.
2.3. Thrombosis and prophylaxis
The diagnosis of symptomatic thrombosis (n = 28),
suspected by either symptoms such as arm swelling, pain
or bluish discoloration, or suspected because of device
malfunctioning (n = 5) was conﬁrmed by duplex ultraso-
nography or phlebography of the upper extremity ve-
nous system, while the investigator was unaware of
any antithrombotic medication.
Before 1998 (n = 66), no prophylaxis with anticoagu-
lants was given, but two patients already received anti-
coagulant treatment with coumarins for various
unrelated reasons, e.g., myocardial infarction, recent
surgery, and remained on coumarin treatment. Since
1998, all patients (n = 177) received thrombosis prophy-
laxis with low molecular weight heparin (LMWH)
(nadroparin 2850 IE s.c. daily), except for the three pa-
tients who had already received coumarin treatment for
other reasons did not receive additional prophylaxis
with LMWH. Five patients received a second catheter
due to catheter-related thrombosis and received
coumarin.2.4. Blood sampling
Since 1999, citrated (room temperature) and acidic
citrated blood (on melting ice) samples were obtained
from 101 patients, after informed consent was ob-
tained. For factor VIII, IX, XI, G1691A (FV) muta-
tion and G20210A (FII) mutation analysis, blood was
collected in tubes containing 0.106 mol/l trisodium ci-
trate. Plasma was prepared by immediate centrifuga-
tion for 10 min at 3200 rotations per minute (rpm)
and stored at 70 C. DNA was extracted from white
cells and the G1691A mutation and G20210A mutation
determined by the polymerase chain reaction (PCR).
The ﬁbrinogen concentration was determined accord-
ing to Clauss [10]. Factor VIII: C [11], factor IX: C
and factor XI: C levels were measured by a one-stage
clotting assay. Elevated levels of factor VIII were de-
ﬁned as >200 IU/dl and of factor IX and factor XI
as >150 IU/dl. For homocysteine concentration assays,
blood was collected in Stabilyte tubes containing 0.5
mol/l trisodium citrate and plasma was prepared by
immediate centrifugation and stored at 70 C. Total
homocysteine concentration was determined with the
high performance liquid chromatography (HPLC) so-
dium borohydride/monobromobimane method
(NaBH4/mBrB method used NaBH4 for reduction
and mBrB derivation) [12]. Elevated levels of homocys-
teine were deﬁned based on the distribution of plasma
levels in cohorts with diﬀerent age and gender. For wo-
men, elevated levels of homocysteine were deﬁned as
greater than 13.4 mmol/l for those aged 19–59 years,
greater than 16.4 mmol/l for those aged 60–70 years
and greater than 17.4 mmol/l for patients over 70 years
of age. For men, this was deﬁned as greater than 15.2
mmol/l for 19–59 year old, greater than 18.3 mmol/l for
those aged 60–70 years and greater than 19.1 mmol/l
for patients over 70 years of age.
2.5. Statistical analysis
We compared catheters in patients who experienced
catheter-related thrombosis with catheters in patients
who did not experience such events.
We investigated putative risk factors by calculating
exposure odd ratios (ORs) as an estimate of the relative
risk (RR). The ORs show how much higher the risk of
disease, e.g., thrombosis, is in the presence of a risk fac-
tor than in its absence. An OR ratio of 1 indicates the
absence of an association.3. Results
Of 243 patients who received 255 devices, in 171
(67%) a catheter was placed in a central vein, i.e., jugular
internal or subclavian vein (‘‘chest ports’’) and in 84
Table 3
Risk of thrombosis in relation to the type of catheter and use of
anticoagulants
Venous thrombosis OR (95% CI)
Arm ports Chest ports
All catheters
(n = 255)
25/84 8/171 8.1 (3.5–19.1)
Without anticoagulants
(n = 64)
13/46 6/18 0.8 (0.2–2.5)
With anticoagulantsa
(n = 191)
12/38 2/153 34.8 (7.3–165)
a Nadroparin (n = 181) or coumarin (n = 10).
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lical vein (‘‘arm ports’’). The mean time in situ for the
chest ports was 207 days (median 178 days; range 9–
1092 days) and for arm ports 352 days (median 321
days; range 7–1795 days).
Thirty-three (14%) of the 243 cancer patients devel-
oped a catheter-related thrombosis during chemother-
apy; 28 (85%) were associated with patient symptoms
and ﬁve detected because of device malfunctioning.
The mean time until detection of thrombosis was 22
days (median 51 days; range 6–309 days), and eighty-ﬁve
percent occurred within 2 months. In four of the 28
(14%) thromboses that occurred within 2 months, the
port was still functioning.
Except for ovarian cancer, there was no association
between tumour type, presence or absence of metastatic
disease, platelet count, number of chemotherapeutic cy-
cles or type of chemotherapy and thrombosis incidence
(Table 1). Both arm and chest posts were implanted
on the right (n = 152) and left (n = 103) side; the risk
of venous thrombosis was 3.5-fold higher for left-sided
placement compared with right-sided placement
(OR = 3.5, 95% CI 1.6–7.5) (Table 2).
The position of the tip of the catheter (atrium versus
cava superior vein) was associated with the risk of ve-
nous thrombosis: the risk was almost 3-fold higher when
the catheter tip was located in the superior vena cava
compared with the atrium (OR = 2.7, 95% CI 1.1–6.6).
We did not ﬁnd an association with the type of catheter,
or the manufacturer. In 8 (5%) of 171 chest ports and 25
(30%) of 84 arm ports, venous thrombosis occurred, i.e.,
the risk of venous thrombosis was 8-fold higher for arm
ports than for chest ports (OR = 8.1 95% CI 3.5–19.1,
Table 3).
In 64 patients who did not receive anticoagulants, the
risk to develop venous thrombosis was similar in pa-
tients with arm ports and patients with chest ports; in
13 (28%) of the 46 arm ports, and 6 (33%) of the 18 chest
ports, venous thrombosis occurred. In patients who re-
ceived anticoagulants (in 95% of the catheters nadropa-
rin s.c. was given) catheter-related venous thrombosis
occurred more often in those with arm ports (12 [32%]
of 38 ports) than in those with chest ports (2 [1%] of
153 ports), OR = 34.8 95% CI 7.3–165 (Table 3). NoneTable 2
Risk of thrombosis in relation to site of placement of catheter
Venous thrombosis OR (95% CI)
Left-sided
placement
Right-sided
placement
All catheters
(n = 255)
22/103 11/152 3.5 (1.6–7.5)
Chest ports
(n = 171)
4/38 4/133 3.8 (0.9–15.9)
Arm ports
(n = 84)
18/65 7/19 1.5 (0.5–4.5)of the 10 patients on coumarin therapy developed ve-
nous thrombosis.
From 101 patients in whom prothrombotic factors
were determined, eighteen (18%) had developed venous
thrombosis. The prevalence of factor V Leiden and pro-
thrombin 20210A did not diﬀer between the group of
patients with venous thrombosis and the group of pa-
tients without evidence of catheter-related thrombosis,
nor did we ﬁnd an association between elevated levels
of FVIII, FIX and FXI and the development of throm-
bosis (Table 4). However, elevated plasma homocysteine
levels were more frequently found in the group of pa-
tients with venous thrombosis (median 12.7 mmol/l;
range 5.4–31.8), i.e., 8 (44.4%) of 18 patients with ve-
nous thrombosis, compared with 14 (16.9%) of 83 pa-
tients without venous thrombosis (median 12.3 mmol/l;
range 8.3–20.1). Elevated plasma homocysteine concen-
tration was associated with a 3.8-fold increased risk of
development of thrombosis (OR = 3.8 95% CI 1.3–
11.3, Table 4), there was no linear correlation between
the actual plasma homocysteine level and thrombosis.4. Discussion
We found an incidence of 14% of catheter-related
thrombosis in cancer patients receiving anthracycline-
and cisplatin-containing combination chemotherapy
via implantable central or peripheral venous ports. Most
cases of venous thrombosis occurred within 2 months
after insertion of the catheter. The administration of
anticoagulants, mainly prophylaxis with s.c. adminis-
tered nadroparin, was associated with a markedly re-
duced incidence of thrombosis for chest, but not for
arm ports. We identiﬁed arm ports, left-sided placement,
catheter tip location in the superior cava vein and ele-
vated levels of homocysteine as important risk factors
for the development of thrombosis.
Platelet counts, the presence of stage IV metastatic
disease, individual cytotoxic drug and the cumulative
dose of the cytotoxic drugs administered, were not asso-
ciated with the development of catheter-related throm-
Table 4
Number of patients with factor V Leiden or factor II 20210A gene mutations, elevated plasma levels of clotting factors or homocysteine
Patients with thrombosis (n = 18) Patients without thrombosis (n = 83) OR (95% CI)
n (%) n (%)
Factor V Leiden/ factor II 20210A mutation 1 (5.6) 7 (8.4) 0.6 (0.1–5.5)
›FVIII 3 (16.7) 6 (7.2) 2.2 (0.5–9.6)
›FIX 4 (22.2) 25 (30.1) 0.9 (0.3–3.2)
›FXI 2 (11.1) 5 (6) 2.0 (0.4–11.0)
›Homocysteine 8 (44.4) 14 (16.9) 3.8 (1.3–11.3)
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risk factor for the development of catheter-related
thrombosis, probably reﬂecting the intrinsically high
risk of developing thrombosis in patients with ovarian
carcinoma [13], compared with other tumour types.
Most studies on peripherally inserted catheters,
although performed in patients with diseases other than
cancer, showed a much lower incidence of thrombosis of
up to 5% [14,15]. In agreement with our ﬁndings,
Kuriakose and colleauges [16] also observed a higher
incidence in peripheral ports of 11% compared with
3% in chest ports in patients with mainly cancer or myel-
oproliferative disorders undergoing chemotherapy.
Left-sided placement as well as location of the cathe-
ter tip in the superior vena cava instead of the right
atrium was found to be associated with a more than 3-
fold respectively 2.6-fold increase in risk for the develop-
ment of thrombosis. The high incidence of thrombosis,
despite the prophylactic use of anticoagulants, found
in patients with arm ports compared with chest ports
may have resulted from arm movements, kinking of
the catheter, mechanical displacement of the catheter,
or a nod in the catheter at the level of the armpit. Such
factors may have contributed to changes in blood ﬂow
or injury of the vascular endothelium and release of clot-
ting activators, especially in cancer patients with periph-
erally inserted arm ports.
Conﬂicting data exist in the literature with regard to
the association between gene abnormalities and the risk
of catheter-related thrombosis in cancer patients. We
found no association between the risk for thrombosis
and known risk factors for venous thrombosis, nor with
elevated levels of factor VIII, IX or XI. This is consist-
ent with our previous data [17] and data from Ramacci-
otti and colleagues [18], who also did not ﬁnd an
association between gene polymorphisms tested, i.e.,
Factor V Leiden, factor II G20210A, factor XIII val
34leu and Methylene tetrahydrofolate reductase
(MTHFR) C677T, and the risk of venous thrombosis
in cancer patients. In agreement with these ﬁndings,
Riordan and colleagues [19] found a low prevalence of
factor V Leiden gene mutation in 28 cancer patients with
catheter-related venous thrombosis. In contrast, other
groups did ﬁnd an association between factor V Leiden
and prothrombin gene mutations and thrombosis inpaediatric [20] and in adult patients with haematological
malignancies [21]. One explanation could be that gene
mutations only carry a low additional risk that does
not have a substantial impact on thrombosis incidence
when other factors already result in a high incidence
of venous thrombosis.
Elevated plasma homocysteine levels have been iden-
tiﬁed as a risk factor for venous thrombosis. Damage of
the endothelial cells by homocysteine has been proposed
as a cause of homocysteine-associated venous thrombo-
sis, but the exact mechanism is unknown [22]. Elevated
levels of homocysteine, as observed in our cancer pa-
tients, may thus play a causative role in the development
of catheter-related thrombosis, in particular during the
administration of endothelial cell-damaging chemother-
apy. In cancer patients, plasma homocysteine levels may
originate from proliferating cancer cells [23]. The role of
elevated homocysteine levels, MTHFR polymorphism,
possibly associated with cancer dietary deﬁciency, and
the protective eﬀect of dietary supplementation in cancer
patients [24,25] clearly deserves further investigation in
larger cohorts of patients. Reduced dietary folate intake
in cancer patients, may well contribute to increased
homocysteine levels and the development of venous
thrombosis in these patients.
The high incidence of thrombosis and the associated
complications rate compel further investigation into the
exact role of elevated homocysteine levels.
Prophylaxis with anticoagulants is a controversial is-
sue at present and policies diﬀer in diﬀerent countries.
The question of whether prophylaxis with either
LMWH or coumarin could protect against catheter-re-
lated venous thrombosis in cancer patients, either solid
tumour or haematological patients, has been addressed
in ﬁve randomised studies, of which three have appeared
as full papers [2,26–29]. Monreal and colleagues [2] and
Bern and colleagues [26] both performed a randomised
placebo-controlled study in solid tumour patients. Both
studies demonstrated that prophylaxis, with LMWH
and warfarin, respectively, could protect against cathe-
ter-related venous thrombosis. In both studies, a venog-
raphy was performed as the end-point in each patient
after 90 days of insertion of the catheter. On the basis
of these two studies, the American College of Chest
Physicians recommended prophylaxis with LMWH or
2258 M.E.T. Tesselaar et al. / European Journal of Cancer 40 (2004) 2253–2259low-dose warfarin in cancer patients with central venous
catheters [30]. More recently, Heaton and colleagues [27]
randomly assigned 88 patients with haematological
malignancies to low-dose warfarin or no treatment.
The end-point of this study was clinically suspected ve-
nous thrombosis, conﬁrmed by venography. No signiﬁ-
cant diﬀerence in venous thrombosis incidence was
found between the warfarin and control groups. More
recently, two randomised studies have been performed
[28,29]. One in mostly haematological malignancy pa-
tients [28] with or without the use of warfarin, and the
other [29] in mostly solid tumour patients, employing
LMWH. In both studies, no major diﬀerences were ob-
served, but the studies have not yet been reported as
peer-reviewed papers.
In conclusion, this is the ﬁrst report identifying ele-
vated plasma homocysteine levels as a major risk factor
for catheter-related thrombosis. As our study was
based on small numbers, further investigation of
homocysteine levels in a larger group of cancer patients
is warranted to unravel the relationship between fac-
tors inﬂuencing plasma homocysteine levels in cancer
patients undergoing chemotherapy and the occurrence
of venous thrombosis. Based on the high incidence of
thrombosis in our patient group, despite the use of
prophylactic anticoagulants, we strongly advise against
the use of arm ports in cancer patients undergoing
anthracycline- and/or cisplatin-based combination
chemotherapy. In contrast, the use of a chest port to
facilitate administration of such chemotherapy is asso-
ciated with a low risk of thrombosis, provided that
thrombotic prophylaxis is given. Our data underscore
the ﬁndings of Monreal and colleagues [2] and Bern
and colleagues [26], with respect to the need for throm-
bosis prophylaxis in cancer patients with central ve-
nous catheters. Conﬂicting data in the literature with
regard to this question may be explained by the ab-
sence of stratiﬁcation for identiﬁed prothrombotic risk
factors (e.g., elevated levels of homocysteine, arm ports
and side of catheter placement) resulting in such fac-
tors not being well balanced between the two random-
ised groups of patients.Conﬂict of interest
None.Acknowledgements
We thank T.C. Visser, LUMC Leiden for performing
the gene mutation analyses and determination of plasma
clotting factors and D. Oppenraaij-Emmerzaal, A. de
Graaf and Dr. H.J. Blom, UMC Nijmegen for determi-
nation of homocysteine levels.References
1. De Cicco M, Matovic M, Balestreri L, Panarello G, Fantin D,
Morassut S, et al.. Central venous thrombosis: an early and
frequent complication in cancer patients bearing long-term
silastic catheter. A prospective study. Thromb Res 1997, 86,
101–113.
2. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R,
et al.. Upper extremity deep venous thrombosis in cancer
patients with venous access devices – prophylaxis with a low
molecular weight heparin (fragmin). Thromb Haemostasis 1996,
75, 251–253.
3. Lokich JJ, Becker B. Subclavian vein thrombosis in patients
treated with infusion chemotherapy for advanced malignancy.
Cancer 1983, 52, 1586–1589.
4. van Rooden CJ, Rosendaal FR, Barge RMY, van Oostayen JA,
van der Meer FJM, Meinders AE, et al.. Central venous catheter
related thrombosis in haematology patients and prediction of risk
by screening with Doppler-ultrasound. Brit J Haematol 2003, 123,
507–512.
5. Lee AY, Levine MN. The thrombophilic state induced by
therapeutic agents in the cancer patient. Semin Thromb Hemost
1999, 25, 137–145.
6. Borow M, Crowley JG. Prevention of thrombosis of central
venous catheters. J Cardiovasc Surg (Torino) 1986, 27, 571–574.
7. Pottecher T, Forrler M, Picardat P, Krause D, Bellocq JP, Otteni
JC. Thrombogenicity of central venous catheters: prospective
study of polyethylene, silicone and polyurethane catheters with
phlebography or post-mortem examination. Eur J Anaesthesiol
1984, 1, 361–365.
8. Puel V, Caudry M, Le Metayer P, Baste JC, Midy D, Marsault C,
et al.. Superior vena cava thrombosis related to catheter malpo-
sition in cancer chemotherapy given through implanted ports.
Cancer 1993, 72, 2248–2252.
9. Simpson KR, Hovsepian DM, Picus D. Interventional radio-
logic placement of chest wall ports: results and complications in
161 consecutive placements. J Vasc Interv Radiol 1997, 8,
189–195.
10. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestim-
mung des Fibrinogens. Acta Haemat 1957, 17, 237–246.
11. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal
FR. Role of clotting factor VIII in effect of von Willebrand
factor on occurrence of deep-vein thrombosis. Lancet 1995,
345, 152–155.
12. Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM. Homocys-
teine and other thiols in plasma and urine: automated determi-
nation and sample stability. Clin Chem 1993, 39, 263–271.
13. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M. Venous
thromboembolism and cancer. Lancet 1998, 351, 1077–1080.
14. Lyon RD, Griggs KA, Johnson AM, Olsen JR. Long-term follow-
up of upper extremity implanted venous access devices in
oncology patients. J Vasc Interv Radiol 1999, 10, 463–471.
15. Foley MJ. Radiologic placement of long-term central venous
peripheral access system ports (PAS Port): results in 150 patients.
J Vasc Interv Radiol 1995, 6, 255–262.
16. Kuriakose P, Colon-Otero G, Paz-Fumagalli R. Risk of deep
venous thrombosis associated with chest versus arm central
venous subcutaneous port catheters: a 5-year single-institution
retrospective study. J Vasc Interv Radiol 2002, 13, 179–184.
17. Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA,
Rosendaal FR, et al.. Thromboembolic events during chemother-
apy for germ cell cancer: a cohort study and review of the
literature. J Clin Oncol 2000, 18, 2169–2178.
18. Ramacciotti E, Wolosker N, Puech-Leao P, Zeratti EA, Gusson
A, del Giglio A, et al.. Prevalence of factor V Leiden, FII
G20210A, FXIII Va134Leu and MTHFR C677T polymorphisms
M.E.T. Tesselaar et al. / European Journal of Cancer 40 (2004) 2253–2259 2259in cancer patients with and without venous thrombosis. Thromb
Res 2003, 109, 171–174.
19. Riordan M, Weiden PL. Factor V Leiden mutation does not
account for central venous catheter-related thrombosis. Am J
Hematol 1998, 58, 150–152.
20. Wermes C, Prondzinski MV, Lichtinghagen R, Barthels M, Welte
KW, Sykora KW. Clinical relevance of genetic risk factors for
thrombosis in paediatric oncology patients with central venous
catheters. Eur J Pediatr 1999, 158, S143–S146.
21. Fijnheer R, Paijmans B, Verdonck LF, Nieuwenhuis HK, Roest
AW, Dekker AW. Factor V Leiden in central venous catheter-
associated thrombosis. Brit J Haematol 2002, 118, 267–270.
22. den Heijer M, Keijzer MBAJ. Hyperhomocysteinemia as a risk
factor for venous thrombosis. Clin Chem Lab Med 2001, 39,
710–713.
23. Wu LL, Wu JT. Hyperhomocysteinemia is a risk factor for cancer
and a new potential tumor marker. Clin Chim Acta 2002, 322,
21–28.
24. Campbell IG, Baxter SW, Eccles DM, Choong DYH. Methyl-
enetetrahydrofolate reductase polymorphism and susceptibility to
breast cancer. Breast Cancer Res 2002, 4.
25. Miao XP, Xing DY, Tan W, Qi J, Lu WF, Lin DX. Susceptibility
to gastric cardia adenocarcinoma and genetic polymorphisms inmethylenetetrahydrofolate reductase in an at-risk chinese popula-
tion. Cancer Epidem Biomar Prev 2002, 11, 1454–1458.
26. Bern MM, Lokich JJ, Wallach SR, Bothe Jr A, Benotti PN, Arkin
CF, et al.. Very low doses of warfarin can prevent thrombosis in
central venous catheters. A randomized prospective trial. Ann
Intern Med 1990, 112, 423–428.
27. Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as
prophylaxis for central vein catheter thrombosis. Int Med J 2002,
32, 84–88.
28. Coubon S, Goodyear M, Burnell M, Dolan S, Wasi P, Macleod
D, et al.. A randomized double-blind placebo controlled study of
low dose warfarin for the prevention of symptomatic central
venous catheter-associated thrombosis in patients with cancer.
Blood 2003, 100(Suppl.), 703a.
29. Reichardt P, Kretzschmar A, Biakhov M, Irwin D, Slabber C,
Miller L, et al.. A Phase III double blind, placebo-controlled
study evaluating the efﬁcacy and safety of daily low-molecular-
weight heparin (dalteparin sodium, fragmin) in preventing cath-
eter-related complications in cancer patients with central venous
catheters. Proc Am Soc Clin Oncol.
30. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW,
Anderson FA, et al.. Prevention of venous thromboembolism.
Chest 2001, 119, 132S–175S.
